<DOC>
	<DOCNO>NCT00199212</DOCNO>
	<brief_summary>The main objective study determine feasibility combination proteasome inhibitor bortezomib ( PS-341 , Velcade ) trastuzumab ( Herceptin ) determine best dose bortezomib combine two trastuzumab schedule , weekly 3-weekly .</brief_summary>
	<brief_title>PS-341 Combination With Herceptin Advanced Breast Cancer That Overexpresses HER-2</brief_title>
	<detailed_description>Phase 1 study determine feasibility combination proteasome inhibitor bortezomib ( PS-341 , Velcade ) trastuzumab ( Herceptin ) give either weekly 3-weekly . Additionally , hint efficacy combination look upon .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>1 . Female gender 2 . Age &gt; = 18 year 3 . ECOG performance status &lt; 2 4 . Histologically proven diagnosis breast cancer 5 . Locally advanced and/or metastatic disease 6 . Life expectancy three month longer 7 . No concurrent second malignancy ( except adequately treat basal cell carcinoma skin , situ carcinoma cervix contralateral breast cancer ) . Any prior second malignancy must remission &gt; = 5 year ( except contralateral breast cancer ) . 8 . No serious illness medical condition include : History document congestive heart failure ; angina pectoris require antianginal medication ; evidence recent ( &lt; 6 month ) transmural infarction electrocardiogram ( ECG ) ; poorly control hypertension ( e.g . systolic &gt; 180 mmHg diastolic great 100 mmHg ) ; clinically significant valvular heart disease ; highrisk uncontrolled arrhythmias . Chronic lung disease History significant neurological psychiatric disorder would prohibit understanding give informed consent , include psychotic disorder , mental retardation , dementia . Active concurrent infection 9 . No symptomatic central nervous system ( CNS ) metastases 10 . No rapidly progressive visceral metastasis require immediate chemotherapy 11 . No concurrent anticancer treatment allow . 12 . Prior investigational biological agent allow , exception antiHER2 therapy reason . 13 . Previous hormonal therapy allow , adjuvant and/or metastatic breast cancer ( MBC ) . 14 . Adjuvant MBC chemotherapy allow , provide minimum 4 week interval elapse last chemotherapy administration first study drug dose . All patient , opinion investigator , could benefit single agent Herceptin® consider suitable treatment chemotherapy plus Herceptin® consider protocol . 15 . A maximum cumulative dose previous doxorubicin &lt; 360 mg/m2 maximum cumulative dose epirubicin &lt; 720 mg/m2 16 . Concomitant use bisphosphonates allow , however bisphosphonates started trial worsen bone pain , patient assess possible progressive disease . 17 . Adequate organ function define : Neutrophils &gt; = 1.5 x 10^9/L Platelets &gt; = 100 x 10^9/L Bilirubin &lt; = 1.5 x upper limit normal ( ULN ) Transaminases &lt; = 2.5 x ULN &lt; = 5 x ULN liver metastasis Creatinine &lt; = 1.5 x ULN 18 . Overexpression HER2 invasive component primary tumor , accord one follow definition : 3+ overexpression immunohistochemistry ( IHC ) 2+ overexpression IHC fluorescence situ hybridization ( FISH ) test demonstrate cerbB2 gene amplification ( ratio cerbB2 gene signal centromere 17 signal &gt; 2 ) 19 . Baseline leave ventricular ejection fraction ( LVEF ) &gt; 50 % measure multiple gated acquisition scan ( MUGA ) echocardiography 20 . Evaluable unidimensionally measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) criteria 21 . Women childbearing potential must negative serum urine pregnancy test willing use acceptable method birth control . 22 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial . 23 . Before patient registration/randomization , informed consent must give accord International Conference Harmonization/European Union Good Clinical Practice ( ICH/EU GCP ) , national/local regulation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>HER-2 positive</keyword>
	<keyword>metastatic breast cancer patient</keyword>
</DOC>